IKZF1 and neoplasm: Intriguingly, knock-down of IKZF1 sensitizes tumor cells in DLBCL to treatment with the EZH2 inhibitor tazemetostat [35], not only emphasizing its biological, but also a possible clinical impact in lymphoma.